Observational study for ATTR amyloidosis patients
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of transthyretin amyloidosis (ATTR).
- You must be 18 years old or older.
- You must be willing to share information about your health through regular questionnaires.
- You cannot be currently taking part in another study testing a treatment for ATTR amyloidosis.
- You must have symptoms of ATTR amyloidosis (this study is not for people who are symptom-free).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study uses PET/CT scans to look at the heart in people who carry a genetic change (TTR mutation) that can cause a heart condition called amyloidosis, and compares them with people who have symptoms and healthy controls. It may help doctors better understand and detect the disease earlier.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
This study evaluates the long-term safety and effectiveness of the study drug ALXN2220 in people with transthyretin amyloid cardiomyopathy. It is an extension of a previous trial, so if you completed the earlier study, you may be able to continue receiving the treatment and be monitored for a longer period.
This study looks at the health records of people with ATTR amyloidosis to understand how the disease is treated and what happens over time. It helps doctors learn more about this condition so they can improve care.
Hear when a new Transthyretin Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.